Neuro-Lift |
|
| BUY THIS PRODUCT:: | PRINT THIS TECH SHEET:: |
|
HIGHLIGHTS::
|
WHAT IS L-TYROSINE?L-Tyrosine is an amino acid that is synthesized in the body from L-Phenylalanine. Tyrosine is involved in energy production and the formation of melanin, and it plays a key role in the synthesis of thyroxin (a hormone secreted by the thyroid gland). Additionally, Tyrosine is the critical precursor to the production of the neurotransmitter dopamine and the hormones norepinephrine and epinephrine. WHAT ARE CATECHOLAMINES?Dopamine, norepinephrine and epinephrine are collectively known as catecholamines. In its role as a precursor in the formation of catecholamines, L-Tyrosine is first converted to dopa, and then to dopamine. Dopamine is then available for conversion to norepinephrine and epinephrine. Catecholamine deficiencies in humans have been linked to depression, and research has shown that low levels of the precursor Tyrosine are also correlated with depression. Further research has revealed that supplementation with L-Tyrosine can be clinically effective in the treatment of depression associated with catecholamine deficiencies. WHY IS N-ACETYL-L-TYROSINE INCLUDED?N-Acetyl-L-Tyrosine is a special Tyrosine chemical complex. Research indicates that it crosses the blood-brain barrier rapidly, and including the N-Acetyl-L-Tyrosine complex improves the effectiveness of the NEURO-LIFT formula. L-TYROSINE AND DEPRESSION::
NEURO-LIFT is a unique blend of the highest quality USP L-Tyrosine (500 mg), N-Acetyl- L-Tyrosine (100 mg), and the active, co-enzymatic form of vitamin B6 (20 mg). L-Tyrosine is a key factor in catecholamine synthesis, and clinical studies have shown that altered catecholamine levels correlate with depression in humans. NEURO-LIFT was designed to safely and effectively increase catecholamine levels. L-TYROSINE AND STRESS::
L-TYROSINE AND COCAINE ADDICTION::
L-TYROSINE AND NARCOLEPSY::
HIGHLIGHTS AND BENEFITS OF NEURO-LIFT::
SAFETY CONSIDERATION::L-Tyrosine is a natural amino acid that has been used safely for over 20 years with no adverse side effects. However, L-Tyrosine and formulations containing L-Tyrosine should not be used by individuals taking MAO inhibitors. In addition, persons with melanomas should not supplement with L-Tyrosine because it is involved in the production of melanin. REFERENCES::Alonso, R., Gibson, C., Wurtman, R.J., Agharanya, J.C., & Prieto, L. (1982). Elevation of urinary catecholamines and their metabolites following tyrosine administration in humans. Biol. Psych. 17(7), 781-790. Dackle, C.A. & Gold, M.S. (1985). Journal of Substance Abuse Treatment. Dakshinamurti, K. (1982). Neurobiology of pyridoxine. In H. Draper (Ed.), Advances in Nutritional Research. (Vol 4, pp.143- 179). New York: Plenum Press. Gibson, C. (1983). Control of monoamine synthesis by amino acid precursors. Adv. Biol. Psychiat. 10, 4-18. Gibson C., & Gelenberg, A. (1983). Tyrosine for the treatment of depression. Adv Biol Psychiat. 10, 148-59. Hitri, A., Casanova, M., Kleinman, J., & Wyatt, R. (1994). Fewer dopamine transporter receptors in the prefrontal cortex of cocaine users. Am.J.Psychiatry, 151, 1074-1076. Kishimoto, H., Hama, Y., Nagasaki, T., & Konno, M. (1978). Plasma amino acid concentrations in depressed patients. Yokaham Med. Bul. Moller, S.E., Odum, K., Kirk, L., Bjerre, M., Fog-Moller, F., & Knudsen, A. (1985). Plasma tyrosine/neutral amino acid ratio correlated with clinical response to nortriptyline in endogenously depressed patients. J Affect Disord. Nov; 9(3), 223-9. Montgomery, S., & Corn, T.H. (1994). Psychopharmacology of depression. Oxford University Press, Oxford, UK. Roufs, J.B. (1990). L-tyrosine in the treatment of narcolepsy. Med Hypotheses. 33(4), 269-73. Salter, C. (1989). Dietary tyrosine as an aid to stress resistance among troops. Mil Med. Mar; 154(3), 144-6. Stone, E.A. (1975). Stress and catecholamines. In A.J. Friedhoff (Ed.), Catecholamines and Behavior 2: Neuropsychopharmacology (pp. 31-72). New York: Plenum Press. Wurtman, R., Hefti, F., & Melamed, E. (1981). Precursor control of neurotransmitter synthesis. Pharmac. Rev. 32, 315-335. |
|
Bright Hope Designs, Website Solutions